Clinically, different treatments (Table 2), such as small or short activating RNAs [22], liver X nuclear receptor (LXR) agonist RGX-104 (not validated in liver cancer) [106], a HepaVac-101 vaccine consisting of multipeptide antigens (IMA970A) plus TLR7/8/RIG-I (retinoic acid-inducible gene I) agonist CV8102 [107], TLR8 agonist (GS-9688) [108], and invariant NKT cells (iNKT) infusion [109], are under investigation in the clinic (https://clinicaltrials.gov/, accessed on 20 November 2023). The gene discussed is RIGI; the disease is liver cancer.